IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells

Jonathan Sherlock(Merck & Co., Inc., Rahway, NJ, USA (United States)), Barbara Joyce-Shaikh(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scott Turner(Merck & Co., Inc., Rahway, NJ, USA (United States)), Cheng‐Chi Chao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Manjiri Sathe(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jeff Grein(Merck & Co., Inc., Rahway, NJ, USA (United States)), Daniel M. Gorman(Merck & Co., Inc., Rahway, NJ, USA (United States)), Edward P. Bowman(Merck & Co., Inc., Rahway, NJ, USA (United States)), Terrill K. McClanahan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jennifer H. Yearley(Merck & Co., Inc., Rahway, NJ, USA (United States)), Gérard Eberl(Institut Pasteur), Christopher D. Buckley(University of Birmingham), Robert A. Kastelein(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert H. Pierce(Merck & Co., Inc., Rahway, NJ, USA (United States)), Drake LaFace(Merck & Co., Inc., Rahway, NJ, USA (United States)), Daniel J Cua(Merck & Co., Inc., Rahway, NJ, USA (United States))
Nature Medicine
July 1, 2012
Cited by 1,037

Abstract


Related Papers

No related papers found

Powered by citation graph analysis